The effects of lower intensity anticoagulation therapy on coagulation system in patients with mechanical prosthetic valves

Abstract

To evaluate the effect of lower intensity anticoagulation therapy in patients with mechanical prosthetic valves, laboratory-based hematological assays including prothrombin time (PT), activity of factor X, antithrombinI (ATI), D-dimer, fibrinogen (Fg) and platel et al pha-granular membrane protein (GMP-140) were performed in 65 patients who had been on warfarin treatment for over one month. The patients were assigned to 3 groups on the basis of their International Normalized Ratios (INR), ranging from 2.00 to 2.50; 2.51 to 3.00; 3.01 to 4.50, respectively. The results showed that the D-dimer, Fg, GMP-140 levels were higher after mechanical valve replacement than those before operation, indicating, the activation of coagulation and fibrinolysis system and the damage of platelets. Lower intensity anticoagulation therapy (INR 2.00 to 2.50) could effectively inhibit the activity of factor X and increase the level of ATI. There were no appreciable differences among D-dimer, Fg, GMP-140 and ATI in the 3 anticoagulation intensity groups. These results suggest that in patients with new generation mechanical prosthetic valves, target anticoagulation level (INR 2.00 to 2.50) may result in good protection from thrombo-embolism.

Keywords

anticoagulation intensity / coagulation system / mechanical prosthetic valve

References

[1] SkudickyD, EssopM R, WisenbaughT, et al. . Frequency of prosthetic valve-related complications with very low level warfarin anticoagulation combined with dipyridamole after valve replacement using St. Jude Medical prostheses. Am J Cardiol, 1994, 74: 1137-1137

[2] HorstkotteD, SchulteH D, BircksW, et al. . Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg, 1994, 107: 1136-1136

[3] WilsonD B, DunnM I, HassaninK. Low-intensity anticoagulation in mechanical cardiac prosthetic valves. Chest, 1991, 100: 1553-1553

[4] 1991, 14:351

[5] EdmundsL H. Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg, 1987, 44: 430-430

[6] SteinP D, AlpertJ S, CopelandJ, et al. . Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest, 1992, 102: 445S-445S

[7] HirshJ, PollerL, DeykinD, et al. . Optimal therapeutic range for oral anticoagulants. Chest, 1989, 95: 5S-5S

[8] PollerL. Therapeutic ranges in anticoagulant administration. Br Med J, 1985, 290: 1683-1683

[9] EdmundsLH. Thromboembolic complications of current cardiac valvular prostheses. Ann Thorac Surg, 1982, 34: 96-96

[10] LoeligerE A. Laboratory control, optimal thrapeutic ranges and therapeutic quality control in oral anti-coagulation. Acta Haematol, 1985, 74: 125-125

[11] ButchartE G, LewisP A, BethelJ A, et al. . Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors. Circulation, 1991, 84: 61-61

[12] AltmanR, RouvierJ, GurfinklE, et al. . Comparison of two levels of anticoagulation therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg, 1991, 101: 427-427